Professional development Vacancies

Regarding amendments to the instructions for medical use of medicinal products containing amiodarone

13.12.2024 867 views

In accordance with paragraph 8 of Section IV of the Procedure for Expert Evaluation, the applicant must amend the instructions for medical use of the medicinal product upon receipt of new data, including bringing the instructions for medical use into line with the approved instructions for medical use of the original (reference) medicinal product, and ensure that the information on the medicinal product corresponds to current scientific knowledge.

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing amiodarone, PSUSA/00000166/202312, reached the following conclusions.

Given the data available in the literature on primary graft dysfunction after heart transplantation, the PRAC considers that a causal relationship between the use of amiodarone and primary graft dysfunction after heart transplantation is at least a reasonable possibility. The PRAC concluded that the instructions for medical use of medicinal products containing amiodarone should be amended accordingly.

Having considered the PRAC recommendations, the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) agrees with the overall conclusions of the PRAC and the grounds for the recommendations.

Based on the scientific conclusions on amiodarone, the CMDh considers that the benefit/risk balance of medicinal products containing amiodarone does not change, provided that the proposed changes are made to the instructions for medical use.

Changes to be made to the relevant sections of the package inserts (new text underlined and in bold).

  • “Special precautions for use” section

The warning should be added as follows:

Primary graft dysfunction after heart transplantation

In retrospective studies, amiodarone use by the recipient before heart transplantation was associated with an increased risk of primary graft dysfunction (PGD). PGD is a life-threatening complication after heart transplantation, manifested as dysfunction of the left, right, or both ventricles, occurring within the first 24 hours after the transplant surgery and having no identified secondary cause (see section “Adverse reactions”). Severe PGD may be irreversible.

Patients on the waiting list for a heart transplant should be considered for an alternative antiarrhythmic agent as early as possible before the transplant.

  • “Adverse reactions” section

The following adverse reaction should be added to the subsection “Injury, poisoning and procedural complications” with the frequency “not known”

Primary graft dysfunction after heart transplantation (see section “Special warnings and precautions for use”)

Changes to the safety information on medicinal products containing amiodarone based on the results of the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) held on 02 – 05 September 2024

The European Medicines Agency (EMA) has published the minutes of the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) held on September 02 – 05, 2024. Following the meeting, a decision was made that safety-related changes need to be introduced to the registration materials/instructions for medical use of medicinal products containing amiodarone.

Amiodarone (amiodarone) – PSUSA/00000166/202312

Amiodarone (amiodarone) – an antiarrhythmic agent indicated for the treatment of a number of cardiac rhythm disorders.

Based on the evaluation of the Periodic Safety Update Reports (PSURs), the PRAC reviewed the benefit/risk balance of medicinal products containing amiodarone and made the following recommendations.

Summary of recommendations and conclusions

  • Based on the analysis of safety and efficacy data, the benefit/risk balance of medicinal products containing amiodarone (amiodarone), for the approved indications remains unchanged.
  • Nevertheless, the instructions for medical use must be updated by adding a warning about primary graft dysfunction after heart transplantation, and primary graft dysfunction after heart transplantation should also be added as an adverse reaction with the frequency “unknown.” Accordingly, the existing provisions of the instructions for medical use must be amended1.

In the next PSUR, registration certificate holders must provide cumulative reviews of potential drug interactions between amiodarone and carbamazepine, and between amiodarone and apixaban/rivaroxaban, and must also carefully monitor the development of BRASH syndrome.

____________________________________________________________________________

1 Update of the sections “Special warnings and precautions for use” and “Adverse reactions” of the package inserts. The risk assessment report and PRAC recommendation are forwarded to the CMDh for a decision.

List of medicinal products containing amiodarone and authorized for medical use in Ukraine (according to the State Register of Medicinal Products as of 05.12.2024).

TO ANALYZE THE PUBLISHED INFORMATION AND SUBMIT THE CORRESPONDING APPLICATION FOR AMENDMENTS TO THE REGISTRATION MATERIALS, THE APPLICANT MUST USE THE ORIGINAL TEXT POSTED AT THE LINKS:

LINK LINK LINK LINK